Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets : implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
SUMMARYThe World Health Organisation's 2022 AWaRe Book provides guidance for the use of 39 antibiotics to treat 35 infections in primary healthcare and hospital facilities. We review the evidence underpinning suggested dosing regimens. Few (n = 18) population pharmacokinetic studies exist for key oral AWaRe antibiotics, largely conducted in homogenous and unrepresentative populations hindering robust estimates of drug exposures. Databases of minimum inhibitory concentration distributions are limited, especially for community pathogen-antibiotic combinations. Minimum inhibitory concentration data sources are not routinely reported and lack regional diversity and community representation. Of studies defining a pharmacodynamic target for ß-lactams (n = 80), 42 (52.5%) differed from traditionally accepted 30%-50% time above minimum inhibitory concentration targets. Heterogeneity in model systems and pharmacodynamic endpoints is common, and models generally use intravenous ß-lactams. One-size-fits-all pharmacodynamic targets are used for regimen planning despite complexity in drug-pathogen-disease combinations. We present solutions to enable the development of global evidence-based antibiotic dosing guidance that provides adequate treatment in the context of the increasing prevalence of antimicrobial resistance and, moreover, minimizes the emergence of resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Clinical microbiology reviews - (2024) vom: 04. März, Seite e0013923 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reza, Nada [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antimicrobial pharmacodynamics |
|---|
| Anmerkungen: |
Date Revised 04.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1128/cmr.00139-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369264371 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369264371 | ||
| 003 | DE-627 | ||
| 005 | 20240304233522.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240304s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/cmr.00139-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM369264371 | ||
| 035 | |a (NLM)38436564 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reza, Nada |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets |b implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a SUMMARYThe World Health Organisation's 2022 AWaRe Book provides guidance for the use of 39 antibiotics to treat 35 infections in primary healthcare and hospital facilities. We review the evidence underpinning suggested dosing regimens. Few (n = 18) population pharmacokinetic studies exist for key oral AWaRe antibiotics, largely conducted in homogenous and unrepresentative populations hindering robust estimates of drug exposures. Databases of minimum inhibitory concentration distributions are limited, especially for community pathogen-antibiotic combinations. Minimum inhibitory concentration data sources are not routinely reported and lack regional diversity and community representation. Of studies defining a pharmacodynamic target for ß-lactams (n = 80), 42 (52.5%) differed from traditionally accepted 30%-50% time above minimum inhibitory concentration targets. Heterogeneity in model systems and pharmacodynamic endpoints is common, and models generally use intravenous ß-lactams. One-size-fits-all pharmacodynamic targets are used for regimen planning despite complexity in drug-pathogen-disease combinations. We present solutions to enable the development of global evidence-based antibiotic dosing guidance that provides adequate treatment in the context of the increasing prevalence of antimicrobial resistance and, moreover, minimizes the emergence of resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a WHO | |
| 650 | 4 | |a antimicrobial pharmacodynamics | |
| 650 | 4 | |a antimicrobial resistance | |
| 650 | 4 | |a global health | |
| 650 | 4 | |a pharmacodynamic targets | |
| 650 | 4 | |a population pharmacokinetics | |
| 700 | 1 | |a Gerada, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Stott, Katharine E |e verfasserin |4 aut | |
| 700 | 1 | |a Howard, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Sharland, Mike |e verfasserin |4 aut | |
| 700 | 1 | |a Hope, William |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology reviews |d 1996 |g (2024) vom: 04. März, Seite e0013923 |w (DE-627)NLM012914312 |x 1098-6618 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:04 |g month:03 |g pages:e0013923 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/cmr.00139-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 04 |c 03 |h e0013923 | ||